Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF mut CD274 pos |
Therapy | Nivolumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | not predictive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF mut CD274 pos | lung non-small cell carcinoma | not predictive | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, BRAF mutant non-small cell lung cancer patients with CD274 (PD-L1) expression >/= 50% did not show a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab) when compared to BRAF mutant patients with CD274 (PD-L1) expression, 0-49%, demonstrating an objective response rate of 36% (4/11) vs 14% (1/7) (p=0.59) and median progression-free survival of 5.3 mo vs 2.2 mo (p=0.73) (PMID: 29723688). | 29723688 |
PubMed Id | Reference Title | Details |
---|---|---|
(29723688) | BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. | Full reference... |